This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schottelius, M. Articles by Wester, H.-J. Search for Related Content PubMed PubMed Citation Articles by Schottelius, M. Articles by Wester, H.-J.

First ¹⁸F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography

¹ Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany; ² Institute of Pathology, University of Berne, Berne, Switzerland; and ³ Institut für Organische Chemie und Biochemie, Technische Universität München, Garching, Germany

ABSTRACT

Purpose: Despite excellent radionuclide characteristics, no ¹⁸F-labeled peptides are available for quantitative peptide receptor mapping using positron emission tomography (PET) so far, mainly due to time-consuming multistep radiosyntheses with limited overall yields. A newly developed two-step chemoselective conjugation method allows rapid and high-yield [¹⁸F]fluorination of peptides via oxime formation and was applied for the synthesis of new ¹⁸F-labeled carbohydrated Tyr³-octreotate (TOCA) analogs with optimized pharmacokinetics suitable for clinical routine somatostatin-receptor (sst) imaging.

Experimental Design: ¹⁸F-labeled glucose (Gluc-S-) and cellobiose (Cel-S-) derivatives of aminooxy-functionalized TOCA were synthesized via oxime formation with 4-[¹⁸F]fluorobenzaldehyde ([¹⁸F]FBOA-peptides). Both the in vitro internalization profile of Gluc-S-Dpr([¹⁸F]FBOA)TOCA and Cel-S-Dpr([¹⁸F]FBOA)TOCA in hsst₂-expressing Chinese hamster ovary cells (dual tracer protocol) and their biodistribution in AR42J tumor-bearing mice were investigated and compared with two [¹⁸F]fluoropropionylated ([¹⁸F]FP) analogs, Gluc-Lys([¹⁸F]FP)TOCA and Gluc-S-Dpr([¹⁸F]FP)TOCA.

Results: In contrast to [¹⁸F]FP-labeling (3 h), chemo-selective [¹⁸F]FBOA-formation (50 min) afforded the respective radiopeptides in high yields (65–85%). In vitro, Gluc-S-Dpr([¹⁸F]FBOA)TOCA and Cel-S-Dpr([¹⁸F]FBOA)-TOCA showed high internalization (139 ± 2 and 163 ± 8 of the reference [¹²⁵I]Tyr³-octreotide, respectively), which was reflected by high tumor accumulation in vivo [21.8 ± 1.4 and 24.0 ± 2.5% of injected dose/g (1 h), respectively]. How-ever, only Cel-S-Dpr([¹⁸F]FBOA)TOCA and Gluc-S-Dpr([¹⁸F]FP)TOCA (tumor: 15.1 ± 1.5% of injected dose/g) with its very low accumulation in all of the nontarget organs showed improved tumor:organ ratios compared with Gluc-Lys([¹⁸F]FP)TOCA. For Cel-S-Dpr([¹⁸F]FBOA)TOCA,tumor:organ ratios (1 h) were 42:1, 27:1, 15:1, 3:1, and 208:1 for blood, liver, intestine, kidney, and muscle, respectively.

Conclusion: Due to the fast and high-yield chemoselective radiofluorination strategy and to its excellent pharmacokinetics, Cel-S-Dpr([¹⁸F]FBOA)TOCA represents the first tracer suitable for routine clinical application in PET somatostatin receptor imaging.

This article has been cited by other articles:

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				E. ZAPANTI and I. ILIAS Pheochromocytoma: Physiopathologic Implications and Diagnostic Evaluation Ann. N.Y. Acad. Sci., November 1, 2006; 1088(1): 346 - 360. [Abstract] [Full Text] [PDF]

				B. L SHULKIN, I. ILIAS, J. C SISSON, and K. PACAK Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 374 - 382. [Abstract] [Full Text] [PDF]

				W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]

				W. Cai, X. Zhang, Y. Wu, and X. Chen A Thiol-Reactive 18F-Labeling Agent, N-[2-(4-18F-Fluorobenzamido)Ethyl]Maleimide, and Synthesis of RGD Peptide-Based Tracer for PET Imaging of {alpha}v{beta}3 Integrin Expression J. Nucl. Med., July 1, 2006; 47(7): 1172 - 1180. [Abstract] [Full Text] [PDF]

				V. Tolmachev, F. Y. Nilsson, C. Widstrom, K. Andersson, D. Rosik, L. Gedda, A. Wennborg, and A. Orlova 111In-Benzyl-DTPA-ZHER2:342, an Affibody-Based Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors J. Nucl. Med., May 1, 2006; 47(5): 846 - 853. [Abstract] [Full Text] [PDF]

				G. Meisetschlager, T. Poethko, A. Stahl, I. Wolf, K. Scheidhauer, M. Schottelius, M. Herz, H. J. Wester, and M. Schwaiger Gluc-Lys([18F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [111In]DTPA-Octreotide J. Nucl. Med., April 1, 2006; 47(4): 566 - 573. [Abstract] [Full Text] [PDF]

				R. Cescato, S. Schulz, B. Waser, V. Eltschinger, J. E. Rivier, H.-J. Wester, M. Culler, M. Ginj, Q. Liu, A. Schonbrunn, et al. Internalization of sst2, sst3, and sst5 Receptors: Effects of Somatostatin Agonists and Antagonists J. Nucl. Med., March 1, 2006; 47(3): 502 - 511. [Abstract] [Full Text] [PDF]

				H.-J. Wester and H. Kessler Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? J. Nucl. Med., December 1, 2005; 46(12): 1940 - 1945. [Full Text] [PDF]

				B. E. Rogers, J. J. Parry, R. Andrews, P. Cordopatis, B. A. Nock, and T. Maina MicroPET Imaging of Gene Transfer with a Somatostatin Receptor-Based Reporter Gene and 94mTc-Demotate 1 J. Nucl. Med., November 1, 2005; 46(11): 1889 - 1897. [Abstract] [Full Text] [PDF]